UBS Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-99,157
| Closed | -$3.42M | – | 9166 |
|
|
2020
Q3 | $3.42M | Buy |
99,157
+14,483
| +17% | +$308K | ﹤0.01% | 2548 |
|
|
2020
Q2 | $1.42M | Buy |
84,674
+22,435
| +36% | +$381K | ﹤0.01% | 3201 |
|
|
2020
Q1 | $898K | Buy |
62,239
+29,175
| +88% | +$746K | ﹤0.01% | 3448 |
|
|
2019
Q4 | $1.11M | Sell |
33,064
-70,416
| -68% | -$1.97M | ﹤0.01% | 4114 |
|
|
2019
Q3 | $2.17M | Buy |
103,480
+67,449
| +187% | +$1.38M | ﹤0.01% | 3207 |
|
|
2019
Q2 | $750K | Buy |
36,031
+19,082
| +113% | +$393K | ﹤0.01% | 3970 |
|
|
2019
Q1 | $379K | Sell |
16,949
-67,894
| -80% | -$1.6M | ﹤0.01% | 4232 |
|
|
2018
Q4 | $2.03M | Buy |
84,843
+75,509
| +809% | +$1.95M | ﹤0.01% | 3026 |
|
|
2018
Q3 | $255K | Sell |
9,334
-230
| -2% | -$6.5K | ﹤0.01% | 4878 |
|
|
2018
Q2 | $257K | Sell |
9,564
-118,670
| -93% | -$3.63M | ﹤0.01% | 4778 |
|
|
2018
Q1 | $4.08M | Buy |
128,234
+114,846
| +858% | +$4.04M | ﹤0.01% | 2501 |
|
|
2017
Q4 | $506K | Sell |
13,388
-4,605
| -26% | -$149K | ﹤0.01% | 4288 |
|
|
2017
Q3 | $446K | Buy |
17,993
+10,449
| +139% | +$225K | ﹤0.01% | 4298 |
|
|
2017
Q2 | $155K | Buy |
7,544
+6,604
| +703% | +$126K | ﹤0.01% | 4909 |
|
|
2017
Q1 | $20K | Sell |
940
-2,637
| -74% | -$54.1K | ﹤0.01% | 6150 |
|
|
2016
Q4 | $73K | Buy |
3,577
+3,477
| +3,477% | +$71.1K | ﹤0.01% | 5534 |
|
|
2016
Q3 | $2K | Sell |
100
-80
| -44% | -$1.08K | ﹤0.01% | 7446 |
|
|
2016
Q2 | $2K | Sell |
180
-2,061
| -92% | -$28K | ﹤0.01% | 7469 |
|
|
2016
Q1 | $30K | Buy |
2,241
+1,641
| +274% | +$25.6K | ﹤0.01% | 5903 |
|
|
2015
Q4 | $11K | Hold |
600
| – | – | ﹤0.01% | 7249 |
|
|
2015
Q3 | $15K | Buy |
+600
| New | +$14K | ﹤0.01% | 6981 |
|
UBS Group's AIMT Position: Q4 2020 in Review
UBS Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 99,157 shares — an estimated $3.42M sold.
UBS Group first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $4.08M in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- UBS Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- UBS Group sold 99,157 Aimmune Therapeutics shares in Q4 2020, an estimated $3.42M.
- UBS Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- UBS Group's Aimmune Therapeutics position peaked at $4.08M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.